
FW: PONE-D-17-35336R1: Final Decision Being Processed - [EMID:52949f520fc5c163]

From: Tamie Nasu (tnasu23@med.nagoya-u.ac.jp)

To: naitoh@med.nagoya-u.ac.jp; y_husna@yahoo.com; jiaxf@ninh.chinacdc.cn; yuankaede@yahoo.co.jp

Date: Friday, February 2, 2018, 06:54 AM GMT+7

Authors:

Please find our paper information, which has been accepted. Tamie

From: em.pone.0.58f867.739cc74d@editorialmanager.com

[mailto:em.pone.0.58f867.739cc74d@editorialmanager.com] **On Behalf Of** PLOS ONE

Sent: Friday, February 2, 2018 2:49 AM

To: Tamie Nakajima <tnasu23@med.nagoya-u.ac.jp>

Subject: PONE-D-17-35336R1: Final Decision Being Processed - [EMID:52949f520fc5c163]

CC: y_husna@yahoo.com, naitoh@med.nagoya-u.ac.jp, yuankaede@yahoo.co.jp, jiaxf2006@126.com, yhayashi@met.nagoya-u.ac.jp, tamada@kinjo-u.ac.jp, kitamori@kinjo-u.ac.jp, iked@mukogawa-u.ac.jp, yamori@cardiacstudy.com

Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet

PONE-D-17-35336R1

Dear Dr. Nakajima,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Michael Bader
Academic Editor
PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

RE: Revised paper

From: Tamie Nasu (tnasu23@med.nagoya-u.ac.jp)
To: y_husna@yahoo.com
Date: Saturday, December 23, 2017, 11:25 AM GMT+7

Dr. Yetti:

Thank you for your revise. Please let me know the version of SPSS used. Tamie

From: husna yetti [mailto:y_husna@yahoo.com]
Sent: Friday, December 22, 2017 5:53 PM
To: Tamie Nasu <tnasu23@isc.chubu.ac.jp>; husna yetti <y_husna@yahoo.com>; Tamie Nasu <tnasu23@med.nagoya-u.ac.jp>
Subject: Revised paper

Dear Prof. Nasu,

Please find my revised version and reply to reviewer in the attach files.

I apologize for late sending my revision to you. my little baby had a fever during this week, and today he is getting better.

Thank you very much.

Sncerey yours,

Husna

On Thursday, December 21, 2017, 11:23:24 AM GMT+7, Tamie Nasu <tnasu23@isc.chubu.ac.jp> wrote:

Dear Dr. Yetti:

Deadline was yesterday! Please send your revised version to tnasu23@med.nagoya-u.ac.jp Tamie

From: husna yetti [mailto:y_husna@yahoo.com]
Sent: Saturday, December 9, 2017 8:10 AM
To: tnasu23@med.nagoya-u.ac.jp
Subject: Bls: RE: RE: FW: PLOS ONE Decision: Revision required [PONE-D-17-35336] - [EMID:268d283996bed4b2]

Dear Prof. Nasu,

OK, Prof.

I understand.

Thank you very much.

Sincerely yours,

Husna

Pada Kam, 7 Des 2017 pada 20:48, Tamie Nasu

<tnasu23@med.nagoya-u.ac.jp> menulis:

Dr. Yetti:

Please complete your revision of sex difference paper until 20, Dec. and send me the revised version as well as reply form to reviewers. I will refer your comments and Dr. Naito's comments, and complete the revised form. Dr. Naito will select the suitable photo of HE stain. Sincerely,
Tamie

From: husna yetti [mailto:y_husna@yahoo.com]
Sent: Thursday, November 30, 2017 9:31 AM
To: tnasu23@med.nagoya-u.ac.jp
Subject: Bls: RE: RE: FW: PLOS ONE Decision: Revision required [PONE-D-17-35336] - [EMID:268d283996bed4b2]

OK, Prof. Thank you very much.

Sincerely yours,

Husna

[Dikirim dari Yahoo Mail di Android](#)

Pada Kam, 30 Nov 2017 pada 6:37, Tamie Nasu

<tnasu23@med.nagoya-u.ac.jp> menulis:

Dr. Yetti:

Dr. Naito will send you the file which you requested. Tamie

内藤先生

Husnaさんに最終ファイルを送ってください。那須民江

From: husna yetti [mailto:y_husna@yahoo.com]
Sent: Thursday, November 30, 2017 6:23 AM
To: Tamie Nasu <tnasu23@med.nagoya-u.ac.jp>
Subject: Re: FW: PLOS ONE Decision: Revision required [PONE-D-17-35336] - [EMID:268d283996bed4b2]

Dear Prof. Nasu,

I am fine, thank you, and hope that you are as well.

Would you please send me the manuscript from PlosOne which have text line number or please give me username and password so I can download directly.

I will read reviewer's comments and reply in weekend.

Sincerely yours,

Husna

On Tuesday, November 28, 2017, 5:39:15 PM GMT+7, Tamie Nasu <tnasu23@med.nagoya-u.ac.jp> wrote:

Dr. Yetti:

How are you?. Please read reviewer's comment, and send me the reply as soon as possible. Tamie

From: em.pone.0.5788da.8b1934d2@editorialmanager.com
[\[mailto:em.pone.0.5788da.8b1934d2@editorialmanager.com\]](mailto:em.pone.0.5788da.8b1934d2@editorialmanager.com) **On Behalf Of** PLOS ONE
Sent: Tuesday, November 28, 2017 6:36 PM
To: Tamie Nakajima <tnasu23@med.nagoya-u.ac.jp>
Subject: PLOS ONE Decision: Revision required [PONE-D-17-35336] - [EMID:268d283996bed4b2]

PONE-D-17-35336
Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet
PLOS ONE

Dear Dr. Nakajima,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jan 12 2018 11:59PM. When you are ready to submit your revision, log on to <http://pone.edmgr.com/> and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

- A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.
- A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.
- An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Bader
Academic Editor
PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSONe_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSONe_formatting_sample_title_authors_affiliations.pdf

2. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. "In this paper, for comparison of sex differences, a part of male data (Table 1 only; Body weight, liver weight, relative liver weight, and levels of serum and liver lipids, serum liver function indices and levels of cytokine) is published in other papers (PMID: 22569299, 23824403). All other data are original including male data."

Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

3. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](#) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be

clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting article that investigated about factors of gender differences on HFC-induced fibrosis in noted NASH model, SHRSP5/Dmcr. I describe the corrections and comments as follows.

1. 97: Liver specimens → Part of the samples
2. 118: in livers → in the livers
3. 159: SPSS: describe formal name
4. 164: in body and liver weights and → in body weight, liver weight, and
5. 165: '~ decreased significantly until 2 weeks in females' is inconsistent with Table 1. Table 1 shows $145 \pm 6^*$ in HFC diet fed female at 2 weeks.
6. 188: 'Serum γ -GTP levels were only detected ~ at 8 and 14 weeks, ~' is inconsistent with Tabel 1. Table 1 shows $15 \pm 0^*$ in HFC fed female at 2 weeks.
7. 202: 'Average serum estradiol ~ were not affected by HFC feeding at any of the time points' is inconsistent with Table 1. Table 1 shows $1.3 \pm 1.5^*$ in HFC diet fed female at 2 weeks.
8. Figures: Image resolution is too low. Histopathological images, numeral, and \pm cannot be recognized.
9. 206: '~liver steatosis to a similar degree in male and female rats.' Images in figure 1A are not appropriate. Liver steatosis looks as more severe in female than male.
10. 236: ' $\pm P < 0.05$ vs. male control.' \pm is not represented as figure 1.
11. 241: '~ increased ~ α -SMA protein ~ in both genders at 8 and 14 weeks' is inconsistent with Figure 2A. Figure 2A shows that HFC diet decreased α -SMA in female at 8 weeks.
12. 400: 'HFC-diet feeding slightly decreased serum estradiol ~' Slightly is not appropriate because there is a significant difference.
13. Considering about NASH in women after menopause, iron concentration in serum or liver seems to be concerned. Please consider it.

6. If you would like your identity to be revealed to the authors, please include your name here (optional).

Your name and review will not be published with the manuscript.

Reviewer #1: (No Response)

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <http://pace.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using

PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.